[{"trial_metadata": {"citation": "Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE. Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy. Diabetes Care. 2012;35:1225-1231.", "drug_name": "Lixisenatide", "phase": "Phase III", "indication": "Type 2 Diabetes", "numeric_trial_duration": 12, "trial_duration": "12-week", "safety_population_definition": "All randomized patients exposed to at least one dose of investigational drug.", "NCT Number": "NCT00688701", "Sponsor": "Sanofi-aventis", "route of adminstration": "Subcutaneous"}, "baseline_table": [{"variable_label": "Mean age", "variable_label_raw": "Mean age (years 6 SD)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "years", "arm_result": {"total_n": 122, "arm_label": "Placebo combined", "arm_role": "control", "n": 0, "percent": 0, "mean": 54.1, "sd": 11.0, "raw_value": "54.1 6 11.0"}}, {"variable_label": "Mean age", "variable_label_raw": "Mean age (years 6 SD)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "years", "arm_result": {"total_n": 120, "arm_label": "Lixisenatide 2-Step", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 53.3, "sd": 9.7, "raw_value": "53.3 6 9.7"}}, {"variable_label": "Mean age", "variable_label_raw": "Mean age (years 6 SD)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "years", "arm_result": {"total_n": 119, "arm_label": "Lixisenatide 1-Step", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 53.8, "sd": 10.9, "raw_value": "53.8 6 10.9"}}, {"variable_label": "Male", "variable_label_raw": "Male, n (%)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "categorical", "units": "%", "arm_result": {"total_n": 122, "arm_label": "Placebo combined", "arm_role": "control", "n": 60, "percent": 49.2, "mean": 0, "sd": 0, "raw_value": "60 (49.2)"}}, {"variable_label": "Male", "variable_label_raw": "Male, n (%)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "categorical", "units": "%", "arm_result": {"total_n": 120, "arm_label": "Lixisenatide 2-Step", "arm_role": "treatment", "n": 63, "percent": 52.5, "mean": 0, "sd": 0, "raw_value": "63 (52.5)"}}, {"variable_label": "Male", "variable_label_raw": "Male, n (%)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "categorical", "units": "%", "arm_result": {"total_n": 119, "arm_label": "Lixisenatide 1-Step", "arm_role": "treatment", "n": 63, "percent": 52.9, "mean": 0, "sd": 0, "raw_value": "63 (52.9)"}}, {"variable_label": "Race", "variable_label_raw": "Caucasian", "categorical_label": "Race, n (%)", "variable_type": "categorical", "units": "%", "arm_result": {"total_n": 122, "arm_label": "Placebo combined", "arm_role": "control", "n": 90, "percent": 73.8, "mean": 0, "sd": 0, "raw_value": "90 (73.8)"}}, {"variable_label": "Race", "variable_label_raw": "Caucasian", "categorical_label": "Race, n (%)", "variable_type": "categorical", "units": "%", "arm_result": {"total_n": 120, "arm_label": "Lixisenatide 2-Step", "arm_role": "treatment", "n": 88, "percent": 73.3, "mean": 0, "sd": 0, "raw_value": "88 (73.3)"}}, {"variable_label": "Race", "variable_label_raw": "Caucasian", "categorical_label": "Race, n (%)", "variable_type": "categorical", "units": "%", "arm_result": {"total_n": 119, "arm_label": "Lixisenatide 1-Step", "arm_role": "treatment", "n": 85, "percent": 71.4, "mean": 0, "sd": 0, "raw_value": "85 (71.4)"}}, {"variable_label": "Race", "variable_label_raw": "Asian", "categorical_label": "Race, n (%)", "variable_type": "categorical", "units": "%", "arm_result": {"total_n": 122, "arm_label": "Placebo combined", "arm_role": "control", "n": 24, "percent": 19.7, "mean": 0, "sd": 0, "raw_value": "24 (19.7)"}}, {"variable_label": "Race", "variable_label_raw": "Asian", "categorical_label": "Race, n (%)", "variable_type": "categorical", "units": "%", "arm_result": {"total_n": 120, "arm_label": "Lixisenatide 2-Step", "arm_role": "treatment", "n": 27, "percent": 22.5, "mean": 0, "sd": 0, "raw_value": "27 (22.5)"}}, {"variable_label": "Race", "variable_label_raw": "Asian", "categorical_label": "Race, n (%)", "variable_type": "categorical", "units": "%", "arm_result": {"total_n": 119, "arm_label": "Lixisenatide 1-Step", "arm_role": "treatment", "n": 29, "percent": 24.4, "mean": 0, "sd": 0, "raw_value": "29 (24.4)"}}, {"variable_label": "Race", "variable_label_raw": "Black", "categorical_label": "Race, n (%)", "variable_type": "categorical", "units": "%", "arm_result": {"total_n": 122, "arm_label": "Placebo combined", "arm_role": "control", "n": 3, "percent": 2.5, "mean": 0, "sd": 0, "raw_value": "3 (2.5)"}}, {"variable_label": "Race", "variable_label_raw": "Black", "categorical_label": "Race, n (%)", "variable_type": "categorical", "units": "%", "arm_result": {"total_n": 120, "arm_label": "Lixisenatide 2-Step", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 0, "sd": 0, "raw_value": "0"}}, {"variable_label": "Race", "variable_label_raw": "Black", "categorical_label": "Race, n (%)", "variable_type": "categorical", "units": "%", "arm_result": {"total_n": 119, "arm_label": "Lixisenatide 1-Step", "arm_role": "treatment", "n": 3, "percent": 2.5, "mean": 0, "sd": 0, "raw_value": "3 (2.5)"}}, {"variable_label": "Race", "variable_label_raw": "Other", "categorical_label": "Race, n (%)", "variable_type": "categorical", "units": "%", "arm_result": {"total_n": 122, "arm_label": "Placebo combined", "arm_role": "control", "n": 5, "percent": 4.1, "mean": 0, "sd": 0, "raw_value": "5 (4.1)"}}, {"variable_label": "Race", "variable_label_raw": "Other", "categorical_label": "Race, n (%)", "variable_type": "categorical", "units": "%", "arm_result": {"total_n": 120, "arm_label": "Lixisenatide 2-Step", "arm_role": "treatment", "n": 5, "percent": 4.2, "mean": 0, "sd": 0, "raw_value": "5 (4.2)"}}, {"variable_label": "Race", "variable_label_raw": "Other", "categorical_label": "Race, n (%)", "variable_type": "categorical", "units": "%", "arm_result": {"total_n": 119, "arm_label": "Lixisenatide 1-Step", "arm_role": "treatment", "n": 2, "percent": 1.7, "mean": 0, "sd": 0, "raw_value": "2 (1.7)"}}, {"variable_label": "Median duration of diabetes", "variable_label_raw": "Median duration of diabetes since diagnosis, years (range)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "years", "arm_result": {"total_n": 122, "arm_label": "Placebo combined", "arm_role": "control", "n": 0, "percent": 0, "mean": 0, "sd": 0, "raw_value": "1.4 (0.2212.5)"}}, {"variable_label": "Median duration of diabetes", "variable_label_raw": "Median duration of diabetes since diagnosis, years (range)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "years", "arm_result": {"total_n": 120, "arm_label": "Lixisenatide 2-Step", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 0, "sd": 0, "raw_value": "1.4 (0.2221.5)"}}, {"variable_label": "Median duration of diabetes", "variable_label_raw": "Median duration of diabetes since diagnosis, years (range)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "years", "arm_result": {"total_n": 119, "arm_label": "Lixisenatide 1-Step", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 0, "sd": 0, "raw_value": "1.1 (0.2223.9)"}}, {"variable_label": "Mean HbA1c", "variable_label_raw": "Mean HbA1c, % 6 SD (NGSP)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "%", "arm_result": {"total_n": 122, "arm_label": "Placebo combined", "arm_role": "control", "n": 0, "percent": 0, "mean": 8.07, "sd": 0.9, "raw_value": "8.07 6 0.9"}}, {"variable_label": "Mean HbA1c", "variable_label_raw": "Mean HbA1c, % 6 SD (NGSP)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "%", "arm_result": {"total_n": 120, "arm_label": "Lixisenatide 2-Step", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 7.98, "sd": 0.9, "raw_value": "7.98 6 0.9"}}, {"variable_label": "Mean HbA1c", "variable_label_raw": "Mean HbA1c, % 6 SD (NGSP)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "%", "arm_result": {"total_n": 119, "arm_label": "Lixisenatide 1-Step", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 8.07, "sd": 0.9, "raw_value": "8.07 6 0.9"}}, {"variable_label": "Mean FPG", "variable_label_raw": "Mean FPG (mmol/L 6 SD)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "mmol/L", "arm_result": {"total_n": 122, "arm_label": "Placebo combined", "arm_role": "control", "n": 0, "percent": 0, "mean": 8.9, "sd": 2.2, "raw_value": "8.9 6 2.2"}}, {"variable_label": "Mean FPG", "variable_label_raw": "Mean FPG (mmol/L 6 SD)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "mmol/L", "arm_result": {"total_n": 120, "arm_label": "Lixisenatide 2-Step", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 9.2, "sd": 2.0, "raw_value": "9.2 6 2.0"}}, {"variable_label": "Mean FPG", "variable_label_raw": "Mean FPG (mmol/L 6 SD)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "mmol/L", "arm_result": {"total_n": 119, "arm_label": "Lixisenatide 1-Step", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 9.0, "sd": 2.0, "raw_value": "9.0 6 2.0"}}, {"variable_label": "Mean 2-h PPG", "variable_label_raw": "Mean 2-h PPG (mmol/L 6 SD)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "mmol/L", "arm_result": {"total_n": 122, "arm_label": "Placebo combined", "arm_role": "control", "n": 0, "percent": 0, "mean": 14.3, "sd": 4.8, "raw_value": "14.3 6 4.8"}}, {"variable_label": "Mean 2-h PPG", "variable_label_raw": "Mean 2-h PPG (mmol/L 6 SD)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "mmol/L", "arm_result": {"total_n": 120, "arm_label": "Lixisenatide 2-Step", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 14.8, "sd": 3.9, "raw_value": "14.8 6 3.9"}}, {"variable_label": "Mean 2-h PPG", "variable_label_raw": "Mean 2-h PPG (mmol/L 6 SD)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "mmol/L", "arm_result": {"total_n": 119, "arm_label": "Lixisenatide 1-Step", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 14.6, "sd": 3.4, "raw_value": "14.6 6 3.4"}}, {"variable_label": "Glucose excursion", "variable_label_raw": "Glucose excursion (mmol/L 6 SD)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "mmol/L", "arm_result": {"total_n": 122, "arm_label": "Placebo combined", "arm_role": "control", "n": 0, "percent": 0, "mean": 4.8, "sd": 3.7, "raw_value": "4.8 6 3.7"}}, {"variable_label": "Glucose excursion", "variable_label_raw": "Glucose excursion (mmol/L 6 SD)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "mmol/L", "arm_result": {"total_n": 120, "arm_label": "Lixisenatide 2-Step", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 5.7, "sd": 3.1, "raw_value": "5.7 6 3.1"}}, {"variable_label": "Glucose excursion", "variable_label_raw": "Glucose excursion (mmol/L 6 SD)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "mmol/L", "arm_result": {"total_n": 119, "arm_label": "Lixisenatide 1-Step", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 5.3, "sd": 3.0, "raw_value": "5.3 6 3.0"}}, {"variable_label": "Mean weight", "variable_label_raw": "Mean weight (kg 6 SD)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "kg", "arm_result": {"total_n": 122, "arm_label": "Placebo combined", "arm_role": "control", "n": 0, "percent": 0, "mean": 86.1, "sd": 22, "raw_value": "86.1 6 22"}}, {"variable_label": "Mean weight", "variable_label_raw": "Mean weight (kg 6 SD)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "kg", "arm_result": {"total_n": 120, "arm_label": "Lixisenatide 2-Step", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 89.0, "sd": 22, "raw_value": "89.0 6 22"}}, {"variable_label": "Mean weight", "variable_label_raw": "Mean weight (kg 6 SD)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "kg", "arm_result": {"total_n": 119, "arm_label": "Lixisenatide 1-Step", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 86.5, "sd": 21, "raw_value": "86.5 6 21"}}, {"variable_label": "Mean BMI", "variable_label_raw": "Mean BMI (kg/m2 6 SD)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "kg/m2", "arm_result": {"total_n": 122, "arm_label": "Placebo combined", "arm_role": "control", "n": 0, "percent": 0, "mean": 31.8, "sd": 6.7, "raw_value": "31.8 6 6.7"}}, {"variable_label": "Mean BMI", "variable_label_raw": "Mean BMI (kg/m2 6 SD)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "kg/m2", "arm_result": {"total_n": 120, "arm_label": "Lixisenatide 2-Step", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 32.3, "sd": 6.7, "raw_value": "32.3 6 6.7"}}, {"variable_label": "Mean BMI", "variable_label_raw": "Mean BMI (kg/m2 6 SD)", "categorical_label": "Demographics and baseline characteristics", "variable_type": "continuous", "units": "kg/m2", "arm_result": {"total_n": 119, "arm_label": "Lixisenatide 1-Step", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 31.7, "sd": 6.6, "raw_value": "31.7 6 6.6"}}], "ae_events": [{"AE_label_raw": "Any TEAE", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Placebo combined", "total_n": 122, "arm_role": "control", "n_with_event": 55, "percent_with_event": 45.1}}, {"AE_label_raw": "Any TEAE", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 2-step", "total_n": 120, "arm_role": "treatment", "n_with_event": 63, "percent_with_event": 52.5}}, {"AE_label_raw": "Any TEAE", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 1-step", "total_n": 119, "arm_role": "treatment", "n_with_event": 65, "percent_with_event": 54.6}}, {"AE_label_raw": "Any serious TEAE", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": false, "is_serious_ae": true, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Placebo combined", "total_n": 122, "arm_role": "control", "n_with_event": 5, "percent_with_event": 4.1}}, {"AE_label_raw": "Any serious TEAE", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": false, "is_serious_ae": true, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 2-step", "total_n": 120, "arm_role": "treatment", "n_with_event": 1, "percent_with_event": 0.8}}, {"AE_label_raw": "Any serious TEAE", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": false, "is_serious_ae": true, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 1-step", "total_n": 119, "arm_role": "treatment", "n_with_event": 0, "percent_with_event": 0}}, {"AE_label_raw": "Discontinuation as a result of a TEAE", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": false, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": true, "is_aesi": false, "arm_result": {"arm_label": "Placebo combined", "total_n": 122, "arm_role": "control", "n_with_event": 1, "percent_with_event": 0.8}}, {"AE_label_raw": "Discontinuation as a result of a TEAE", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": false, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": true, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 2-step", "total_n": 120, "arm_role": "treatment", "n_with_event": 5, "percent_with_event": 4.2}}, {"AE_label_raw": "Discontinuation as a result of a TEAE", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": false, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": true, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 1-step", "total_n": 119, "arm_role": "treatment", "n_with_event": 3, "percent_with_event": 2.5}}, {"AE_label_raw": "Gastrointestinal disorders (any)", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Placebo combined", "total_n": 122, "arm_role": "control", "n_with_event": 17, "percent_with_event": 13.9}}, {"AE_label_raw": "Gastrointestinal disorders (any)", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 2-step", "total_n": 120, "arm_role": "treatment", "n_with_event": 39, "percent_with_event": 32.5}}, {"AE_label_raw": "Gastrointestinal disorders (any)", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 1-step", "total_n": 119, "arm_role": "treatment", "n_with_event": 38, "percent_with_event": 31.9}}, {"AE_label_raw": "Nausea", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Placebo combined", "total_n": 122, "arm_role": "control", "n_with_event": 5, "percent_with_event": 4.1}}, {"AE_label_raw": "Nausea", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 2-step", "total_n": 120, "arm_role": "treatment", "n_with_event": 29, "percent_with_event": 24.2}}, {"AE_label_raw": "Nausea", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 1-step", "total_n": 119, "arm_role": "treatment", "n_with_event": 24, "percent_with_event": 20.2}}, {"AE_label_raw": "Headache", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Placebo combined", "total_n": 122, "arm_role": "control", "n_with_event": 14, "percent_with_event": 11.5}}, {"AE_label_raw": "Headache", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 2-step", "total_n": 120, "arm_role": "treatment", "n_with_event": 10, "percent_with_event": 8.3}}, {"AE_label_raw": "Headache", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 1-step", "total_n": 119, "arm_role": "treatment", "n_with_event": 9, "percent_with_event": 7.6}}, {"AE_label_raw": "Vomiting", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Placebo combined", "total_n": 122, "arm_role": "control", "n_with_event": 0, "percent_with_event": 0}}, {"AE_label_raw": "Vomiting", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 2-step", "total_n": 120, "arm_role": "treatment", "n_with_event": 9, "percent_with_event": 7.5}}, {"AE_label_raw": "Vomiting", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 1-step", "total_n": 119, "arm_role": "treatment", "n_with_event": 8, "percent_with_event": 6.7}}, {"AE_label_raw": "Dizziness", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Placebo combined", "total_n": 122, "arm_role": "control", "n_with_event": 3, "percent_with_event": 2.5}}, {"AE_label_raw": "Dizziness", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 2-step", "total_n": 120, "arm_role": "treatment", "n_with_event": 9, "percent_with_event": 7.5}}, {"AE_label_raw": "Dizziness", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 1-step", "total_n": 119, "arm_role": "treatment", "n_with_event": 4, "percent_with_event": 3.4}}, {"AE_label_raw": "Nasopharyngitis", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Placebo combined", "total_n": 122, "arm_role": "control", "n_with_event": 4, "percent_with_event": 3.3}}, {"AE_label_raw": "Nasopharyngitis", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 2-step", "total_n": 120, "arm_role": "treatment", "n_with_event": 6, "percent_with_event": 5}}, {"AE_label_raw": "Nasopharyngitis", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 1-step", "total_n": 119, "arm_role": "treatment", "n_with_event": 5, "percent_with_event": 4.2}}, {"AE_label_raw": "Symptomatic hypoglycemia", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Placebo combined", "total_n": 122, "arm_role": "control", "n_with_event": 2, "percent_with_event": 1.6}}, {"AE_label_raw": "Symptomatic hypoglycemia", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 2-step", "total_n": 120, "arm_role": "treatment", "n_with_event": 3, "percent_with_event": 2.5}}, {"AE_label_raw": "Symptomatic hypoglycemia", "event_category": "Adverse events reported in \u22655% of participants", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Lixisenatide 1-step", "total_n": 119, "arm_role": "treatment", "n_with_event": 1, "percent_with_event": 0.8}}]}]